🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 73 Manchester 28 Sutton 25 Birmingham 17 Cambridge 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72 Clear sponsor filter
Site city
London73 Manchester28 Sutton25 Birmingham17 Cambridge15
All 92 cities
Target enrolment
to
73 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
272
London, Salford, Southampton, Stevenage
2024-04-09
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
Janssen Research & Development, LLC
Phase 3
120
Glasgow, London, Manchester, Oxford, Sheffield
2024-03-13
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
774
London, Reading, Salford, Southampton
2024-02-01
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth
2024-01-22
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
Janssen Research & Development, LLC
Phase 1
300
London, Oxford
2023-12-20
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
London
2023-11-06
Active, closed
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115Plaque Psoriasis
Janssen Research & Development, LLC
Phase 3
684
Harrow, London, Reading, Salford
2023-10-12
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Bristol, Clydebank, Dorchester, Exeter, High Wycombe, Lincoln, London, Sheffield
2023-04-11
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Edinburgh, London, Plymouth, Scunthorpe, Sheffield, Stevenage, Truro
2023-03-23
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Recruiting
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC
Phase 2
520
Cheltenham, Devon, Edinburgh, Leicester, London, Nottingham, Portsmouth
2022-11-11
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 1
196
London, Manchester, Oxfordshire
2022-10-04
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC
Phase 2/3
201
Birmingham, Devon, Glasgow, London, Sheffield
2022-09-23
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford
2022-09-19
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
London, Manchester
2022-08-12
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634Myositis
Janssen Research & Development, LLC
Phase 2
36
Edinburgh, London, Salford
2022-07-05
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Leicester, London
2022-03-01
Rows per page Showing 26–50 of 73
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.